Table 1.
Baseline characteristics of included pre-clinical studies.
| Study | Nutritional component | Timing (and mode) of administration | Brain injury model | Primary outcome measure |
|---|---|---|---|---|
| van de Looij et al., 2014 | Lactoferrin | Pre- and post-treatment (enteral, in maternal diet) | HI P3 rat | Lesion size, myelination |
| Ginet et al., 2016 | Lactoferrin | Pre- and post-treatment (enteral, in maternal diet) | LPS i.c. P3 rat | Lesion size, myelination |
| Xu et al., 2015 | Acetyl-l-carnitine | Post-treatment (s.c.) | HI P7 rat | Lesion size |
| Tang et al., 2016 | Acetyl-l-carnitine | Post-treatment (s.c.) | HI P7 rat | Lesion size, behavior |
| Zhu et al., 2016 | Taurine | Post-treatment (i.p.) | HI P7 rat | Lesion size |
| Mori et al., 2017 | Glycine | Pre-treatment (i.p.) | HI P7 rat | Lesion size |
| Liu et al., 2017 | L-cysteine | Post-treatment (i.p.) | HI P7 mouse | Lesion size, behavior |
| Xin et al., 2018 | L-cysteine | Post-treatment (i.p.) | HI P7 mouse | Lesion size, behavior |
| Berman et al., 2009 | DHA | Pre-treatment (i.p.) | HI P7 rat | Lesion size, behavior |
| Revuelta et al., 2016 | DHA | Pre-treatment (i.p.) | HI P7 rat | Myelination |
| Arteaga et al., 2017 | DHA | Pre-treatment (i.p.) | HI P7 rat | Lesion size, myelination, behavior |
| Berman et al., 2010 | DHA | Pre-treatment (i.p.) | HI+ LPS P7 rat | Lesion size, behavior |
| Williams et al., 2013 | tri-DHA tri-EPA | Post-treatment (i.p.) | HI P10 mouse | Lesion size |
| Mayurasakorn et al., 2016 | tri-DHA tri-EPA | Post-treatment (i.p.) | HI P10 mouse | Lesion size, behavior |
| Berman et al., 2013 | DHA | Post-treatment (i.p.) | HI P7 rat | Lesion size, behavior |
| Solberg et al., 2017 | DHA | Post-treatment (i.v.) | HR newborn piglet | Lipid peroxidation |
| Huun et al., 2018 | DHA | Post-treatment (i.v.) | HR newborn piglet | Lipid peroxidation |
| Buddington et al., 2018 | PS-DHA | Post-treatment (enteral) | Preterm-born piglet | Brain weight, myelination |
| Jaworska et al., 2017 | Na-butyrate | Post-treatment (i.p.) | HI P7 rat | Lesion size |
| Ziemka-Nalecz et al., 2017 | Na-butyrate | Post-treatment (i.p.) | HI P7 rat | Behavior |
| Ramani et al., 2017 | Vitamin A | Post-treatment (enteral) | Hyperoxia P2–14 mouse | Behavior |
| Miura et al., 2009 | Vitamin C | Pre-treatment (i.p.) | HI P7 rat | Macroscopical lesion size |
| Koning et al., 2017 | MgSO4 | Pre-treatment (i.p.) | HI P7 rat | Lesion size |
| Seyama et al., 2018 | MgSO4 | Pre-treatment (i.p.) | HI P6 rat | Myelination |
i.p., intraperitoneal; i.v., intravenous; s.c., subcutaneous; i.c., intracranial; HI, hypoxia-ischemia; HR, hypoxia-reoxygenation; P, postnatal day; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; tri, triglyceride; PS, phosphatidylserine; Na, sodium; MgSO4, magnesiumsulphate.